The Trump administration has officially initiated a broad request for public input regarding potential regulatory overhauls aimed at dismantling sophisticated fraud schemes targeting federal healthcare programs, specifically within the rapidly expanding sector of genetic and molecular diagnostic testing. This move, spearheaded by the Centers for Medicare and Medicaid Services (CMS), signals an aggressive pivot toward heightened oversight of laboratory services, which have seen a dramatic rise in both clinical utility and criminal exploitation over the last two decades. The Request for Information (RFI), published in late February, seeks to gather actionable data from stakeholders to inform a proposed rule that would expand the agency’s toolkit for identifying and neutralizing suspicious billing patterns before they result in significant taxpayer losses.
This regulatory inquiry is not an isolated action but rather a cornerstone of a multi-pronged enforcement package designed to safeguard the integrity of the Medicare and Medicaid programs. Alongside the RFI, the administration has implemented a six-month moratorium on the enrollment of new durable medical equipment (DME), prosthetics, orthotics, and supplies providers in Medicare. Additionally, the federal government has paused $259.5 million in Medicaid funding to Minnesota as part of an ongoing investigation into questionable claims. Together, these actions underscore a systemic effort to address vulnerabilities in the healthcare supply chain that fraudulent actors have increasingly exploited.
The Evolution of Genetic Testing Fraud: A Chronological Overview
The focus on genetic testing is the result of a multi-year escalation in fraudulent activities that have successfully siphoned billions of dollars from federal coffers. Federal law enforcement agencies, including the Department of Justice (DOJ), the Federal Bureau of Investigation (FBI), and the Department of Health and Human Services’ Office of Inspector General (HHS-OIG), have been tracking this trend through a series of high-profile "takedowns."
In 2019, one of the largest healthcare fraud schemes in U.S. history was uncovered in an operation known as "Operation Double Helix." This investigation resulted in federal charges against 35 individuals, including the owners of several telemedicine companies and clinical laboratories. The defendants were alleged to have participated in a scheme that billed Medicare more than $2.1 billion for medically unnecessary genetic tests. The methodology involved "recruiters" who targeted elderly citizens at health fairs, senior centers, and nursing homes. These beneficiaries were often persuaded to provide cheek swabs for "free" cancer screenings or pharmacogenetic testing, despite the tests not being ordered by their actual treating physicians.
The trend continued into the 2020s, adapting to the rise of remote healthcare. In 2023, another major enforcement action saw 49 defendants charged in connection with over $1.17 billion in fraudulent claims. This scheme relied heavily on telemedicine platforms where doctors, often paid kickbacks, signed off on orders for genetic tests and DME without ever meeting or properly evaluating the patients. These historical precedents have provided the CMS with a clear roadmap of the vulnerabilities inherent in the current reimbursement structure, leading directly to the current RFI.
Analyzing the Economic Impact: Spending vs. Volume
The impetus for the CMS’s current focus is grounded in startling financial data. According to an HHS-OIG report released in January, genetic testing has claimed a disproportionately large share of Medicare Part B laboratory spending. In 2024, Medicare paid approximately $8.4 billion for all laboratory tests. While genetic tests accounted for only 5% of the total volume of tests performed, they represented a staggering 43% of the total spending.
This disparity highlights the high cost of molecular diagnostics compared to routine blood work or chemistry panels. For comparison, in 2018, genetic testing accounted for just 18% of Part B lab spending. The fact that this share has more than doubled in six years suggests either a massive shift in clinical practice or, as regulators fear, a surge in the billing of high-cost, unnecessary services. Legal experts note that because these tests can cost thousands of dollars per claim, even a small percentage of fraudulent actors can cause significant financial damage to the Medicare Trust Fund.
Despite the high costs, industry advocates point out that total laboratory services still represent less than 1% of total Medicare spending. However, the rapid growth trajectory of the genetic testing market—driven by advancements in personalized medicine and oncology—makes it a high-priority area for "program integrity" efforts.
The Role of MolDX as a Regulatory Blueprint
Central to the CMS’s inquiry is the Molecular Diagnostic Services program, commonly known as MolDX. Currently administered by the Medicare administrative contractor Palmetto GBA, MolDX was developed to identify and establish coverage and reimbursement for molecular diagnostic tests. The program currently sets policies for 28 states and requires laboratories to register their tests and submit clinical evidence to demonstrate that the tests are "reasonable and necessary."
The CMS is now asking stakeholders whether the MolDX model should be expanded or made mandatory on a national scale. Currently, many Medicare Advantage organizations and private payers in non-MolDX states voluntarily require labs to register with the program because of its reputation for rigorous vetting. Expanding this program would likely involve:
- Mandatory Registration: Requiring all labs performing molecular diagnostics to obtain a unique identifier for each test.
- Clinical Evidence Reviews: Ensuring that every billed genetic test has a proven clinical utility for the specific patient population.
- Enhanced Data Analytics: Using MolDX data to flag labs that show "outlier" billing patterns compared to their peers.
While MolDX is viewed by some as an effective shield against fraud, others in the legal and laboratory community warn of the administrative burden. Danielle Sloane, an attorney at Bass, Berry and Sims, noted that many legitimate labs operate on thin margins and that the costs of complying with expanded MolDX requirements could be prohibitive. "If there’s going to be expanded use of the MolDX program, the government should provide consistency and oversight to make sure it is applied uniformly," Sloane stated, emphasizing the need for a balance between oversight and innovation.
Industry Reactions and the "Chilling Effect" on Innovation
The response from the professional laboratory community has been a mixture of support for anti-fraud measures and concern over regulatory overreach. Susan Van Meter, president of the American Clinical Laboratory Association (ACLA), expressed the trade group’s support for the CMS initiative, noting that fraudulent actors "undermine trust in legitimate healthcare services."
However, Van Meter and other industry leaders are urging the CMS to adopt an "evidence-based approach" that does not impede patient access to advanced diagnostics. Precision diagnostics are the cornerstone of personalized medicine, allowing doctors to tailor treatments to a patient’s genetic profile, thereby avoiding ineffective treatments and reducing long-term costs.
Legal analysts, including Caroline Farrell of Foley Hoag, have raised concerns that the Trump administration’s aggressive enforcement stance could conflict with its broader goal of deregulation. While the administration has frequently touted a desire to cut "red tape" to spur American innovation, the implementation of complex anti-fraud regulations could have a "chilling effect." Farrell warned that companies might hesitate to expand into new diagnostic areas or develop innovative test types if they fear becoming a target of broad federal investigations. "The devil’s going to be in the details," Farrell noted, suggesting that the precision of the new regulations will determine whether they stop criminals or stifle legitimate businesses.
Broader Implications and Future Outlook
The outcome of the RFI, for which comments are being accepted through March 30, will likely serve as the foundation for a new set of federal rules governing how laboratories interact with the Medicare program. This could include stricter enrollment criteria for new labs, more frequent audits of molecular diagnostic claims, and a more robust use of artificial intelligence to detect fraudulent billing in real-time.
For the Trump administration, this crackdown serves two purposes: it reinforces a commitment to "law and order" within the federal bureaucracy and seeks to find "efficiency" by eliminating waste, fraud, and abuse rather than cutting benefits. For beneficiaries, the impact may be felt in how they access testing; while the goal is to protect them from "cheek swab" scammers at health fairs, there is a risk that more stringent prior-authorization requirements could delay legitimate diagnostic results.
As the healthcare industry moves toward a future defined by genomic data, the tension between fostering innovation and preventing exploitation remains at the forefront of policy debates. The CMS’s next steps will be closely watched by investors, healthcare providers, and the millions of seniors who rely on the promise of precision medicine. The federal government’s ability to refine its detection strategies without creating an insurmountable barrier for legitimate laboratories will be the ultimate measure of the program’s success.